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ABSTRACT
Objective To evaluate mortality and cancer incidence
in a cohort of ammonium perfluorooctanoate (APFO)
exposed workers.
Methods We linked a combined cohort (n=9027) of
employees from APFO and non-APFO production
facilities in Minnesota to the National Death Index and
to cancer registries of Minnesota and Wisconsin.
Industrial hygiene data and expert evaluation were used
to create a task-based job exposure matrix to estimate
APFO exposure. Standardised mortality ratios were
estimated using Minnesota population rates. HRs and
95% CIs for time-dependent cumulative APFO exposure
were estimated with an extended Cox model. A priori
outcomes of interest included cancers of the liver,
pancreas, testes, kidney, prostate and breast, and
mortality from cardiovascular, cerebrovascular and
chronic renal diseases.
Results Mortality rates in the APFO-exposed cohort
were at or below the expected, compared with
Minnesota. The HR for dying from the cancer and non-
cancer outcomes of interest did not show an association
with APFO exposure. Similarly, there was little evidence
that the incident cancers were associated with APFO
exposure. Compared to the non-exposed population,
modestly elevated, but quite imprecise HRs were
observed in the higher-exposure quartiles for bladder
cancer (HR=1.66, 95% CI 0.86 to 3.18) and pancreatic
cancer (HR=1.36, 95% CI 0.59 to 3.11). No association
was observed between APFO exposure and kidney,
prostate or breast cancers.
Conclusions This analysis did not support an
association between occupational APFO exposure and
the evaluated health endpoints, however, the study had
limited power to evaluate some conditions of interest.
BACKGROUND
Ammonium perfluorooctanoate (APFO, CAS No.
3825-26-1, C7F15COO
− NH4) is the ammonium
salt of perfluorooctanoic acid (CAS No. 335-67-1,
PFOA, C7F15COOH), and has been used as a
surface-active agent in the polymerisation process
for many fluoropolymers. APFO and PFOA are not
metabolised, but rapidly dissociate in blood to the
perfluorooctanoate anion (C7F15COO
−) where it
readily binds to serum proteins. Two chronic
feeding studies of APFO in rats have reported
increased incidence of hepatocellular adenomas,1
pancreatic cell adenomas1 and hyperplasia,2 3 and
Leydig cell adenomas of the testes.1 2 PFOA is an
agonist for several xenosensor nuclear receptors
(PPARα, CAR/PXR) that result in an early hepato-
cellular proliferative response, but this mode of
action is unlikely to pose a risk in humans.4 5
Occupational exposures in the manufacture of
APFO and its use as a surface-acting agent in fluoro-
polymer production have resulted in serum PFOA
measured in workers at low μg/mL levels.6 7 PFOA
has also been measured in the serum of the general
population at low ng/mL concentrations.8 9 General
population exposures include direct (eg, food and
water) and indirect (eg, biotransformation of fluoro-
telomer alcohols) sources.10 Contamination of drink-
ing water sources has resulted in higher average
serum PFOA concentrations of the affected commu-
nities than the general population, but below occupa-
tional levels.6 7 11 Concerns over the widespread
environmental presence of PFOA and another per-
fluorooctanyl compound, perfluorooctanesulfonate
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What this paper adds?
▸ The human health effects of ammonium
perfluorooctanoate (APFO) and
perfluorooctanoic acid (PFOA) continue to be
investigated. Studies of occupationally exposed
population have reported associations between
APFO and PFOA exposure and certain diseases,
including prostate and kidney cancers, and
diabetes and chronic renal disease.
▸ In this analysis, we update a mortality study of
an APFO production cohort with an improved
exposure reconstruction, add a
non-APFO-exposed referent population from the
same company, and include a linkage to cancer
registries to evaluate incident cancers.
▸ This study does not support previously reported
associations in this cohort between APFO
exposure and risk of prostate and kidney cancer
and diabetes, and stroke, or associations with
kidney cancer and chronic renal disease in
another occupational cohort. This analysis does
not support an association between APFO and
liver and pancreatic cancers in humans. The
study, however, had limited power to evaluate
exposure response for some outcomes,
particularly testicular, thyroid, bladder, liver and
pancreatic cancers.
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(PFOS), led to the phase-out by a major manufacturer, 3M
Company, in 2000–2002. A 2006 PFOA stewardship programme
of the US EPA and eight manufacturers is targeting the complete
phase-out of PFOA by 2015.
Studies in occupationally exposed populations have yielded
some evidence, albeit inconsistent, of potential health effects in
humans. A cohort mortality study of the DuPont Washington
Works (Parkersburg, West Virginia, USA) polytetrafluoroethylene
(PTFE) plant, where APFO was used as a processing aid,
reported chronic renal disease and kidney cancer associated
with increasing occupational exposure to PFOA.12
Tetrafluoroethylene (TFE) exposure was highly correlated with
PFOA exposure, and TFE is a kidney carcinogen in rats.13
Consonni et al14 examined the effect of this joint exposure of
PFOA and TFE in a multiplant cohort study of TFE synthesis
and polymerisation workers that included a sizable subset of
workers from the DuPont Washington Works plant. Estimated
units of exposure to TFE and PFOA were developed but were
highly correlated, thus, the independent causal association of
PFOA and TFE with kidney cancer could not be identified.
Analyses of employees at the 3M Company APFO production
site in Cottage Grove, Minnesota, reported higher risks of death
from prostate cancer and stroke among the highest exposed pro-
duction workers compared to the lowest.15 16 These analyses
were limited by the qualitative nature of the exposure assess-
ment and that the lowest exposed members of the population
were more likely to be research and development professionals
with lower overall baseline risks.
Here we present an updated mortality analysis and a new
cancer incidence analysis of the Cottage Grove cohort and a
non-exposed referent population from a nearby 3M Company
plant. The current study includes an extensive task-based job
exposure data matrix (EDM) for APFO using industrial hygiene
air monitoring data. Based on the epidemiological and toxico-
logical literature as well as the previous findings reported at the
Cottage Grove plant a priori outcomes of interest included
cancers of the liver, pancreas, testes, kidney, prostate and breast,
and mortality from cardiovascular, cerbrovascular and chronic
renal diseases.
METHODS
The protocol for this study was reviewed and approved by the
Human Subjects Committee of the University of Minnesota.
Study population
The study population included employees of two 3M facilities
in the Minneapolis and Saint Paul metropolitan area who had
accrued at least 365 days of employment. The 365-day restric-
tion was implemented to ensure the study population repre-
sented the working population, and excluded short-term
employment, such as students who may have interned for one
or more summers. The APFO production facility was located in
Cottage Grove, Minnesota. The Cottage Grove plant was con-
structed in 1947 and APFO production began soon thereafter.
APFO production increased over time, but was phased out com-
pletely by the end of 2002. Eligible Cottage Grove employees
(n=4668) included 3993 from the previous study and 675 hired
between 1997 and 2002. The Cottage Grove site had two divi-
sions; chemical and non-chemical. The Chemical Division devel-
oped and produced APFO and other specialty chemicals
(non-APFO). The Non-Chemical Division manufactured a
variety of products (not involving APFO), including abrasives,
films, glass bubbles, tape and automotive applications (traffic
signs and mats for catalytic converters). The Chemical and
Non-Chemical Divisions housed research and development and
pilot production activities, thus, the cohort included many non-
production workers.
For a completely non-APFO-exposed production worker ref-
erent population we used a second 3M Company cohort that
had been previously enumerated by the University of
Minnesota. This referent cohort included 4359 employees of a
tape and abrasives production facility in Saint Paul, Minnesota,
who worked for at least 365 days before 1999. This population
was similar to the APFO production workers as production
workers employed by the company, and also located in the same
geographic region and were represented by the same labour
union. The total population of both locations included 9027
workers. A small group of 200 workers had employment
records in both locations. These workers were included in the
Cottage Grove population for the purpose of this analysis of
APFO exposure.
Determination of vital status and causes of death
We completed a vital status assessment on all cohort members
not identified as deceased in the previous follow-up.16 The
cohort was submitted to the Social Security Administration’s
(SSA) service for epidemiologic studies to identify the deceased
and confirm status of living cohort members. A commercial
skip-tracing vendor was used to further explore the vital status
of workers who were not clearly identified as alive or deceased
through the SSA. We submitted all cohort members not deter-
mined to be alive to the National Death Index (NDI). The date
of death, state of death, and underlying and contributing cause
of death were obtained for all matches. Ultimately, the vital
records search confirmed vital status for all but 61 (0.67%)
members of the cohort. The causes of death were coded to the
International Classification of Disease (ICD) version in effect at
the time of death. The complete mortality records were avail-
able through 2008.
Cancer incidence
The company facilities were located in east central Minnesota
close to the Wisconsin border, and some members of the cohort
resided in Wisconsin. We identified incident cancers of interest
through a linkage to the Minnesota Cancer Surveillance System
(MCSS) and the Wisconsin Cancer Reporting System (WCRS).
Both registries operate under state statute requiring mandatory
reporting of cancer diagnoses for state residents. The MCSS was
established in 1988. WCRS was established in 1976 as a passive
system and became mandatory in the late 1980s. A protocol was
developed to permit linkage of the occupational cohort to the
cancer registry to identify selected cancers and return deidenti-
fied data for analysis. All cohort members alive as of 1 January
1988 were eligible for the cancer incidence follow-up. Cancer
incidence, including date of diagnosis, cancer site and histology,
was obtained for a selected set of cancers; liver, pancreas, testes,
prostate, kidney, bladder, breast and thyroid. A potential source
of bias in cancer cases ascertainment was out-migration from
Minnesota and Wisconsin. In lieu of a comprehensive mechan-
ism to evaluate out-migration for the entire cohort, we evalu-
ated the state of death from the mortality records for decedents
alive in 1988. The proportion of deaths occurring in Minnesota
and Wisconsin was used as a surrogate measure of the case
capture of the cohort.
Exposure assessment and exposure models
Production of APFO was a multistep process. PFOA was pro-
duced by electrochemical fluorination and then isolated and
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converted first to an APFO salt slurry, and then to a salt cake.
The cake was dried and/or dissolved in water, packaged, and
shipped to external customers. The production process offered
several opportunities for worker exposure. Inhalation exposure
occurred from the acid vapour and ammonium salt particulate
phase during regular production duties and other responsibilities,
such as cleaning the equipment, changing filters, quality control
checks and maintenance. Additionally, low-level continuous
exposure to APFO occurred from working in and around the
general production environment without direct involvement in
chemical production. We used work history records, industrial
hygiene monitoring data, information from current and former
workers and industrial hygiene professionals, and average annual
APFO production levels to characterise occupational APFO
exposure. Exposure estimates represented inhalation exposure
for all cohort members expressed as a daily time-weighted
average (TWA) in milligrams per cubic metre of air (mg/m3).
Work history records, which included the job department, job
title and start and end dates, were used to identify the duration
and calendar period of employment.
The industrial hygiene data characterising APFO exposure
was limited to APFO production areas in the Chemical Division
(205 personal samples and 659 area samples). The data were
from 1977 through 2000, but represented all processes and
tasks related to production. The production processes prior to
1977 involved the same procedures and tasks, but the exposures
were less due to lower production volume. A TWA was calcu-
lated for each combination of department, job title, work area,
equipment, task and year to create an EDM that contained 23
departments and 45 job titles within the Chemical Division for
all production years (1947–2002). The task-based exposure
model incorporated the amount of time spent during an 8 h
shift in up to three predefined work task areas; (1)
exposure-associated tasks in the production area, (2) non-
exposure tasks in the production area, and (3) tasks outside of
the production area. TWAs for jobs in APFO production ranged
from 1×10−4 to 4.0×10−1 mg/m3.
Job, department and time-specific TWAs were estimated for
non-APFO production areas of the Chemical Division and the
entire Non-chemical Division based on expert judgment that
was informed by the relative proximity of the job to the produc-
tion area and annual APFO production levels. The exposures
for non-APFO production jobs in the Chemical Division ranged
from 1×10−8 to 3×10−5 mg/m3. The exposure range within the
Non-Chemical Division was considered to be between 1×10−8
and 1×10−6 mg/m3. Because of the widespread environmental
presence of PFOA, all cohort members received some exposure
from outside the workplace. The Saint Paul Plant workers were
assigned a background level (1×10−9–1×10−7 mg/m3) to reflect
exposures in the general population equivalent to an exposure
range one order of magnitude lower than the Non-Chemical
Division workers.
The average annual production of APFO varied with fewer
than 500 pounds produced in the early 1950s to around
360 000 pounds in the 1990s. This variation was incorporated
into the average annual TWA for production and non-
production exposure estimates. We linked the department, job
and year-specific TWAs to the employees’ work history records.
We calculated cumulative estimates of exposure based on the
summation of daily TWAs by year.
Data analyses
The initial analysis compared the mortality experience of the
cohort to that of the population of Minnesota. Complete
referent data were available from 1960 onwards, thus, our mor-
tality analysis was limited to deaths occurring between 1960
and 2008. Follow-up was from the date of eligibility to date of
death or the end of 2008. We estimated age, sex, and calendar
period standardised mortality ratios (SMR) for each location
and by quartile of the cumulative APFO exposure distribution
for the Cottage Grove cohort. Data on race were not available
for the cohort. SMR and 95% CIs were computed using the
National Institute of Occupational Safety and Health’s (NIOSH)
software for Life Table Analysis System,17 which incorporates
exposure as a time-dependent covariate.
To compare the APFO-exposed population with the non-
exposed population, HR with 95% CIs for mortality and cancer
incidence risk were estimated as a function of APFO time-
dependent exposure using extended Cox regression models.18
In these models, the Saint Paul workers were the referent popu-
lation and APFO exposure in the Cottage Grove population was
classified into quartiles. The time scale was age, beginning at the
date of first employment for the mortality analysis and the later
of date of first employment or 1 January 1988 (when registry
data were available) for cancer incidence. Follow-up continued
until death, diagnosis of the cancer of interest or end of
follow-up. Models were adjusted for year of birth and sex. The
analyses were conducted using the PHREG procedures in SAS
V.9.2 (SAS Institute Incorporated, Cary, North Carolina, USA).
RESULTS
The cohort of 9027 experienced 2979 deaths. The cohort
members from the two plants were similar in age of first
employment, but the Saint Paul cohort was, on average, born
9 years earlier (table 1). Women represented only 12% of the
Saint Paul cohort compared to 21% in Cottage Grove. Of the
2979 deaths, there were 72 prostate cancers, 48 pancreatic
cancers, 16 bladder cancers, 25 female breast cancers, 24 kidney
cancers and 15 liver cancers.
The SMRs for the Cottage Grove and Saint Paul cohorts
revealed few differences in mortality rates with the state of
Minnesota. Cottage Grove had lower SMRs for all causes
(SMR=0.85, 95% CI 0.80 to 0.90), all cancers (SMR=0.87,
95% CI 0.78 to 0.97), and ischaemic heart disease (SMR=0.84,
95% CI 0.74 to 0.95) (table 2). The Saint Paul workers had
higher rates of death from diabetes than the state of Minnesota
population (SMR=1.42, 95% CI 1.09 to 1.81) (table 2). Few
Table 1 Characteristics of cohort members from the Cottage





n (%) 4668 4359 9027
Male (%) 3716 (79) 3834 (88) 7550 (84)
Female (%) 952 (21) 526 (12) 1478 (16)
Deaths (%) 1145 (25) 1834 (42) 2979 (33)
Eligible for cancer
follow-up (%)
4231 (90.6) 3787 (86.9) 8018 (88.8)
Mean (SD) Mean (SD) Mean (SD)
Year of birth 1942 (16.3) 1933 (14.6) 1938 (16.1)
Age at first employment 29.3 (8.9) 28.6 (8.3) 29 (8.6)
Age at follow-up 63.2 (14.1) 68.8 (11.5) 65.9 (13.2)
APFO, ammonium perfluorooctanoate.
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SMRs by APFO exposure quartile were elevated for any of the
outcomes, and those were not beyond chance (table 3).
To evaluate the risk of death in the APFO population com-
pared to the Saint Paul workers, the exposure categories for
kidney, bladder, liver and breast cancers were collapsed into
high (Q3/4) and low (Q1/2) due to a small number of deaths
from these causes. The workers with the higher APFO exposure
(quartiles 3 or 4) had modestly elevated risk of death from pros-
tate cancer (Q4: HR=1.32, 95% CI 0.61 to 2.84), bladder
cancer (Q3–4: HR=1.96, 95% CI 0.63 to 6.15), and chronic
renal disease (Q4: HR=1.37, 95% CI 0.38 to 4.95), but the
effects were not beyond chance. There was no evidence of ele-
vated risk for kidney cancer. The cohort in the lowest quartile
of APFO exposure had lower risks of death from prostate
cancer (HR=0.34, 95% CI 0.25 to 1.60), cerebrovascular
disease (HR=0.57, 95% CI 0.32 to 1.02), and diabetes
(HR=0.27, 95% CI 0.10 to 0.76) (table 4).
The incident cancer linkage identified the following cancers
of interest (number of cases): prostate (441), kidney (35),
pancreas (25), bladder (83), liver (9), breast (62), testes (5) and
thyroid (5). No exposure response analysis was conducted for
liver, testicular and thyroid cancers due to the small number of
cases. Exposure categories were collapsed for the analysis of
pancreatic cancer, and in supplemental analyses for breast and
kidney cancer. For all cancers of interest there was little evi-
dence that exposure to APFO increased the risk of cancer
(table 5). The lowest-exposure quartiles in the Cottage Grove
population had modestly lower risks for prostate cancer
(HR=0.80, 95% CI 0.57 to 1.11), and the highest exposure
was not substantially different than the referent population
(HR=1.11, 95% CI 0.82 to 1.49). The analysis for kidney
cancer was restricted to men as no women were diagnosed with
kidney cancer. The risk of kidney cancer in the APFO exposed
cohort did not differ appreciably with that of the non-APFO
exposed population. The HRs for pancreatic cancer for the two
highest quartiles combined (HR=1.36, 95% CI 0.59 to 3.11),
and the two highest quartiles for bladder cancer were elevated,
but the CIs were wide. The lowest exposed quartile had a lower
risk of breast cancer compared with the Saint Paul facility
(HR=0.36, 95% CI 0.16 to 0.79), and there was little evidence
that higher exposure to APFO increased the risk of breast
cancer. The results did not change appreciably when the expo-
sures were lagged by 10 years (data not shown).
The analysis of potential impact of out-migration from the
mortality records identified 2059 decedents alive in 1988.
Overall, 85.8% had death certificates from Minnesota or
Wisconsin. For exposure quartiles 1 through 4, the percentage
was 68.8, 77.4, 88.6, and 90.7%, respectively, and 88.8% for
the Saint Paul facility. This distribution lends support to our
assertion that the higher exposed Cottage Grove workers are
more similar to the Saint Paul workers than the lower exposed
Cottage Grove workers. It also suggests a lower case ascertain-
ment in the Cottage Grove employees who had less exposure.
DISCUSSION
In this analysis of APFO production facility workers, we did not
observe an association between APFO exposure and the risk of
several diseases of interest when compared to a non-
APFO-exposed population from the same company. Previous ana-
lyses of the Cottage Grove cohort reported an elevated risk of
Table 2 Standardised mortality ratios (SMR) for selected causes of
death for the Cottage Grove and Saint Paul cohorts
Cause Cottage Grove Plant Saint Paul Plant
Obs SMR (95% CI) Obs SMR (95% CI)
All causes 1125 0.85 (0.80 to 0.90) 1829 0.98 (0.94 to 1.03)
All cancers 332 0.87 (0.78 to 0.97) 514 1.04 (0.95 to 1.13)
Liver cancer 8 0.81 (0.35 to 1.59) 7 0.55 (0.22 to 1.14)
Pancreatic cancer 18 0.85 (0.50 to 1.34) 30 1.09 (0.74 to 1.56)
Prostate cancer 24 0.83 (0.53 to 1.23) 48 1.03 (0.76 to 1.37)
Kidney cancer 6 0.53 (0.20 to 1.16) 18 1.23 (0.73 to 1.95)
Breast cancer 11 0.82 (0.41 to 1.47) 15 1.39 (0.78 to 2.29)
Bladder cancer 8 0.89 (0.38 to 1.76) 8 0.62 (0.27 to 1.22)
Diabetes mellitus 27 0.76 (0.50 to 1.11) 64 1.42 (1.09 to 1.81)
Ischaemic heart
disease
248 0.84 (0.74 to 0.95) 444 0.95 (0.87 to 1.05)
Cerebrovascular
disease
57 0.81 (0.61 to 1.05) 112 1.02 (0.84 to 1.23)
Chronic renal disease 14 1.09 (0.60 to 1.84) 13 0.72 (0.38 to 1.24)
Table 3 Standardised mortality ratios (SMR) by APFO exposure quartile in the Cottage Grove Population and the Saint Paul population
Cause
Cottage Grove Plant exposure quartile* St Paul Plant
Q1 Q2 Q3 Q4
Obs SMR (95% CI) Obs SMR (95% CI) Obs SMR (95% CI) Obs SMR (95% CI) Obs SMR (95% CI)
All causes 317 0.82 (0.74 to 0.99) 261 0.79 (0.70 to 0.90) 334 0.93 (0.83 to 1.03) 213 0.86 (0.75 to 0.98) 1829 0.98 (0.94 to 1.03)
All cancers 79 0.70 (0.55 to 0.87) 81 0.89 (0.71 to 1.11) 103 1.01 (0.82 to 1.22) 69 0.92 (0.71 to 1.16) 514 1.04 (0.95 to 1.13)
Liver cancer 4 1.40 (0.38 to 3.58) 2 0.86 (0.10 to 3.09) 2 0.75 (0.09 to 2.72) 0 0.00 (0.00 to 1.79) 7 0.55 (0.22 to 1.14)
Pancreatic cancer 2 0.32 (0.04 to 1.17) 5 1.00 (0.32 to 2.33) 5 0.87 (0.28 to 2.04) 6 1.41 (0.52 to 3.06) 30 1.09 (0.74 to 1.56)
Prostate cancer 5 0.66 (0.21 to 1.54) 8 1.15 (0.50 to 2.27) 3 0.37 (0.08 to 1.07) 8 1.29 (0.56 to 2.54) 48 1.03 (0.76 to 1.37)
Kidney cancer 1 0.32 (0.01 to 1.77) 2 0.74 (0.09 to 2.69) 2 0.66 (0.08 to 2.38) 1 0.42 (0.01 to 2.34) 18 1.23 (0.73 to 1.95)
Breast cancer 5 0.80 (0.26 to 1.86) 3 0.88 (0.18 to 2.56) 2 0.73 (0.09 to 2.62) 1 1.02 (0.03 to 5.69) 15 1.39 (0.78 to 2.29)
Bladder cancer 1 0.40 (0.01 to 2.25) 2 0.93 (0.11 to 3.38) 4 1.61 (0.44 to 4.13) 1 0.53 (0.01 to 2.97) 8 0.62 (0.27 to 1.22)
Diabetes mellitus 4 0.39 (0.11 to 1.00) 4 0.47 (0.13 to 1.20) 11 1.17 (0.58 to 2.09) 8 1.14 (0.49 to 2.24) 64 1.42 (1.09 to 1.81)
Ischaemic heart disease 73 0.88 (0.69 to 1.11) 60 0.81 (0.62 to 1.04) 68 0.82 (0.64 to 1.04) 47 0.88 (0.64 to 1.17) 444 0.95 (0.87 to 1.05)
Cerebrovascular disease 13 0.62 (0.33 to 1.05) 13 0.73 (0.39 to 1.24) 19 0.97 (0.58 to 1.52) 12 1.02 (0.53 to 1.78) 112 1.02 (0.84 to 1.23)
Chronic renal disease 6 1.61 (0.59 to 3.50) 2 0.63 (0.08 to 2.27) 3 0.87 (0.18 to 2.54) 3 1.24 (0.26 to 3.63) 13 0.72 (0.38 to 1.23)
*Quartile cut-points: 2.6×10−5, 1.4×10−4, 7.3×10−4 mg/m3 years.
APFO, ammonium perfluorooctanoate.
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death from prostate cancer in the highest-exposed category.15 16
This association was not observed in other studies of
APFO-exposed workers.12 19 The small number of deaths and the
relatively crude nature of the exposure assessment limited the
interpretation of these prior analyses. Moreover, the associations
reported by Lundin et al16 were observed in the internal analysis
only, and potentially a function of the very low rate of prostate
cancer death in the lowest-exposure group, a mix of production,
research and development, and administration workers who may
differ from production workers. We addressed this limitation in
this updated study by including the Saint Paul plant workers who
were similar to the Cottage Grove manufacturing workers, but not
exposed to APFO on the job. We also included incident cases of
prostate cancer, thus identifying six times as many cases. While the
SMRs remained inconsistent across PFOA quartile levels, the HRs
for prostate cancer incidence did not suggest a trend. Prostate
cancer mortality and incidence have not been associated with
PFOA exposure in other populations.12 19–21 A recent case-control
study in a population without occupational exposure reported an
association with PFOA among prostate cancer cases who had a
first-degree relative with the same diagnosis.22
In contrast with our study, PFOA was associated with kidney
cancer mortality among DuPont Parkersburg, WV plant
workers.12 In that plant, the ammonium salt of PFOA was used
as a processing aid in the polymerisation of TFE. TFE is a
kidney carcinogen in rats,13 whereas PFOA is not.2 Although
PFOA and TFE exposures were highly correlated, Steenland and
Woskie12 considered only PFOA in their analysis indicating that
they assumed that TFE’s volatile and explosive properties meant
it would be well controlled under normal operations, and thus
render appreciable exposure to it unlikely. By contrast, another
evaluation of TFE synthesis and polymerisation workers (includ-
ing 40% from the DuPont plant),14 23 reported potential TFE
exposure occurring through leaks, opening autoclaves in the
polymerisation area, or from decomposition of the polymer. A
job-exposure matrix with annual semiquantitative estimates for
TFE and PFOA were considered sufficient to identify relative
differences in exposure to both compounds. Consonni et al14
reported an SMR of 1.4 (95% CI 0.7 to 2.7) for kidney cancer
in the cohort, but could not separate the effects of TFE and
PFOA with kidney cancer in their exposure trend analyses. It is
possible the results of Steenland and Woskie12 are similarly con-
founded by TFE.
With concern for the PFOA-TFE exposure overlap, we con-
ducted an extensive review of all potential exposure to TFE at
the Cottage Grove site for production operations, which indi-
cated that exposures were low and infrequent. The highest
volume and most frequent use of TFE occurred in 1982 in a
Table 4 HRs for selected causes of death comparing APFO
exposure quartiles to the referent population
Cancer Exposure* HR 95% CI
Prostate Referent 1
Q1 0.34 0.25 to 1.60
Q2 1.12 0.53 to 2.37
Q3 0.36 0.11 to 1.17
Q4 1.32 0.61 to 2.84
Kidney Referent 1
Q1–Q2 0.38 0.11 to 1.23
Q3–Q4 0.39 0.11 to 1.32
Pancreatic cancer Referent 1
Q1 0.32 0.08 to 1.35
Q2 0.89 0.34 to 2.31
Q3 0.82 0.32 to 2.12
Q4 1.23 0.50 to 3.00
Bladder cancer Referent 1
Q1–Q2 1.03 0.27 to 3.96
Q3–Q4 1.96 0.63 to 6.15
Liver cancer Referent 1
Q1–Q2 2.09 0.69 to 6.31
Q3–Q4 0.67 0.14 to 3.27
Breast cancer Referent 1
Q1–Q2 0.61 0.25 to 1.48
Q3–Q4 0.54 0.15 to 1.94
Chronic renal disease Referent 1
Q1 2.24 0.82 to 6.12
Q2 0.94 0.21 to 4.23
Q3 1.15 0.32 to 4.09
Q4 1.37 0.38 to 4.95
Ischaemic heart disease Referent 1
Q1 0.93 0.73 to 1.18
Q2 0.87 0.66 to 1.13
Q3 0.88 0.68 to 1.13
Q4 0.89 0.66 to 1.21
Cerebrovascular disease Referent 1
Q1 0.57 0.32 to 1.02
Q2 0.70 0.39 to 1.24
Q3 0.93 0.57 to 1.53
Q4 0.98 0.53 to 1.81
Diabetes Referent 1
Q1 0.27 0.10 to 0.76
Q2 0.42 0.17 to 1.04
Q3 0.80 0.42 to 1.51
Q4 0.72 0.34 to 1.52
*Quartile cut-points: 2.9×10−5, 1.5×10−4, 7.9×10−4 mg/m3 years.
APFO, ammonium perfluorooctanoate.
Table 5 HRs for selected cancers comparing APFO exposure
quartiles to the referent population
Cancer Exposure* n HR† 95% CI
Prostate Referent‡ 253 1
Q1 42 0.80 0.57 to 1.11
Q2 42 0.85 0.61 to 1.19
Q3 49 0.89 0.66 to 1.21
Q4 55 1.11 0.82 to 1.49
Kidney Referent 19 1
Q1 4 1.07 0.36 to 3.16
Q2 4 1.07 0.36 to 3.17
Q3 4 0.98 0.33 to 2.92
Q4 4 0.73 0.21 to 2.48
Referent 19 1.0
Q1–Q2 8 1.07 0.46 to 2.46
Q3–Q4 8 0.85 0.36 to 2.06
Pancreatic cancer Referent 15 1
Q1–Q2 1 0.13 0.02 to 1.03
Q3–Q4 9 1.36 0.59 to 3.11
Bladder cancer Referent 43 1
Q1 7 0.81 0.36 to 1.81
Q2 6 0.78 0.33 to 1.85
Q3 15 1.50 0.80 to 2.81
Q4 12 1.66 0.86 to 3.18
Breast cancer Referent 28 1
Q1 8 0.36 0.16 to 0.79
Q2 8 0.65 0.29 to 1.42
Q3 14 1.47 0.77 to 2.80
Q4 4 0.85 0.29 to 2.46
Referent 28 1
Q1–Q2 16 0.46 0.25 to 0.87
Q3–Q4 18 1.27 0.70 to 2.31
*Quartile cut-points: 2.9×10−5, 1.5×10−4, 7.9×10−4 mg/m3 years.
†HR adjusted for year of birth and age.
‡Referent population=Saint Paul Plant.
APFO, ammonium perfluorooctanoate.
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pilot plant with, at most, 12 employees potentially exposed for
only short-duration tasks across shifts. Infrequent and low
volume use occurred in two time periods, 1979–1981 and
1983–1990, when fewer than four workers could have had
minimal exposure to TFE due to the frequency of operations
and control systems. No TFE was used in any operations on the
Cottage Grove site prior to 1978 or after 1991. Monitoring
data and potential exposure tasks indicated that full-shift TWA
TFE exposures were below 0.02 ppm for the highest-volume
production year (1982) and 0.002 ppm other years with low
production. These levels are more than 100 times below the
occupational exposure limit. These factors indicate our study
presented an opportunity to address APFO exposure in near iso-
lation. The absence of an APFO-kidney cancer association sug-
gests prior associations of PFOA/APFO with kidney cancer may
be due to confounding from TFE exposure.
Our results are consistent with the lack of epidemiologic evi-
dence in humans for liver cancer associated with PFOA, as the
populations previously studied were highly exposed occupa-
tional workers,12 a lesser-exposed community through drinking
water,19 21 and the general population.20 We observed a modest
HR for pancreatic cancer for the combined two highest quar-
tiles of PFOA exposure in our study. A non-significant trend for
pancreatic cancer and plasma PFOA levels was reported in a
Danish case-cohort study of the general population.20 Pancreatic
cancer was not reported to be associated with PFOA in other
studies where the population was exposed at much higher
levels12 or through drinking water that contained PFOA.19 21
Because of its low case-fatality rate, testicular cancer is not
well characterised by mortality data.12 We observed too few
incident testicular cancers to perform an exposure-response ana-
lysis. As part of the C8 Health Project, Barry et al19 reported a
trend for testicular cancer in a community cohort exposed to
PFOA. From the same project, an analysis using other cancers as
the referent population, Vieira21 also reported an increased risk
for testicular cancer in a water district that had PFOA in the
water; five neighbouring water districts with lesser amounts of
PFOA in the water did not have increased risks for testicular
cancer.
Butenhoff et al,5 reported a suspected increased incidence of
mammary gland adenomas in rats, but the distribution was
within published background variation. A subsequent pathology
working group re-examined the histology and confirmed no
statistically significant differences between treatment groups.24 A
small case-control study (n=31 cases) reported a modest associ-
ation between diagnosed breast cancer and serum PFOA, but
the postdiagnostic PFOA measurement made the results difficult
to interpret.25 We did not observe an increased incidence of
breast cancer in this occupational cohort, nor was it observed in
a combined community/occupational cohort study.19
An epidemiologic controversy exists whether PFOA is asso-
ciated with higher cholesterol levels in humans in contrast with
the hypolipidemic effect as a PPARα agonist in rodents.26 The
magnitude of the cholesterol effect in humans has been incon-
sistently reported across PFOA exposure levels of these predom-
inantly cross-sectional studies.27 Fletcher et al28 recently
suggested PFOA may promote a hypercholesterolemic environ-
ment with potential implications for human disease as they
studied 290 individuals of an exposed community who had an
inverse association between PFOA and whole-blood expression
of a subset of genes involved with cholesterol mobilisation. Our
finding of a lack of an association for cardiovascular disease or
stroke mortality in this highly exposed PFOA cohort concurs
with similar results from another occupational cohort.12
Increased trends for the incidence of heart disease and stroke
were not consistently reported among a series of analyses under-
taken to assess risk in a community whose drinking water con-
tained PFOA.29–31
Some limitations should be considered when interpreting the
results of this analysis. The new EDM incorporated substantial
task-based detail, but there was potential for exposure misclassi-
fication, particularly from episodic peak exposures. While
EDMs are not well suited for capturing such events, it is likely
the workers were already classified in the high-exposure cat-
egory. We also did not have information on lifestyle factors or
other jobs: a common problem in occupational cohorts. A
non-APFO production site was included as a referent population
to partially address these concerns, as they should have similar
frequencies of these lifestyle and other occupational exposure
factors. Linking the cohort to the Minnesota and Wisconsin
cancer registries provided an excellent opportunity to more
fully explore cancer risks potentially associated with APFO
exposure. Nevertheless, the follow-up for cancer incidence was
limited to 1988 onward. It is likely we missed incident, but non-
fatal cancers occurring before 1988. This is particularly a con-
sideration for thyroid and testicular cancer for which incidence
peaks at earlier ages. Finally, the cancer registries did not cover
cohort members who left Minnesota and Wisconsin and, based
on the proportion of deaths outside these states, there was an
under-ascertainment of cancer cases in the two lower-exposed
quartiles of the Cottage Grove workers.
Notable strengths of this study are the completeness of
follow-up, the improved exposure reconstruction, and the near
absence of TFE exposure. The ability to link this cohort to two
cancer registries allowed for a better examination of the burden
of cancers that are not highly fatal. The inclusion of a large
non-APFO-exposed referent population was also a strength. The
exposure estimates for the APFO production areas were based
on objective monitoring data, but the estimates for non-APFO
production areas in the Chemical Division, the Non-Chemical
Division, and the Saint Paul Plant workers were based on expert
judgment. Though limited, some available biomonitoring data
provide a measure of external validity for the exposure categori-
sations developed from PFOA air monitoring and professional
judgment used in the present study. A PFOA biomonitoring pro-
gramme was offered to Chemical Division employees in con-
junction with medical surveillance activities in 1993, 1995,
1997 and 2000.6 32 33 PFOA concentrations for the 148 partici-
pants in 2000 were log normally distributed with a geometric
mean serum PFOA concentration of 815 ng/mL (95% CI 608 to
1094 ng/mL). This was similar to previous cross-sectional bio-
monitoring surveys of this occupational population.32 The 50
participants who worked only in the PFOA-related manufactur-
ing areas had a geometric mean serum PFOA concentration of
2538 ng/mL (95% CI 1626 to 3961 ng/mL). The 38 Chemical
Division employees whose job involved some work in PFOA
manufacturing areas had a geometric mean PFOA of 979 ng/mL
(95% CI 565 to 1695 ng/mL). The 60 Chemical Division
employees who had never worked in these PFOA manufacturing
areas had a geometric mean PFOA of 282 ng/mL (95% CI 194
to 410 ng/mL). By contrast, 100 American Red Cross blood
donors from the Minneapolis–Saint Paul area in 2000–2001
had a geometric mean serum PFOA concentration of 4.5 ng/mL
(95% CI 4.1 to 4.7 ng/mL),34 which was similar to results from
the nationally representative sample determined from the
National Health and Nutrition Examination Survey in 1999–
2000.35 A study assumption was that the Non-Chemical
Division workers likely had serum PFOA levels lower than the
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Chemical Division workers who never worked in the PFOA
manufacturing area but higher than those reported in the
general population. The biomonitoring data support our asser-
tion that indirect occupational exposure existed at the site.
In summary, we did not observe an association between occu-
pational APFO exposure and the risk of dying or developing
liver, pancreatic, testicular, kidney, prostate, breast, bladder, and
thyroid, cancers, though the power to evaluate some cancers
was limited. We also did not see evidence of elevated risks of
mortality from ischaemic heart disease, cerebrovascular disease,
or chronic renal disease.
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